INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake Immunotherapeutics - MLTX

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of MoonLake Immunotherapeutics regarding potential securities fraud or unlawful business practices [1] - MoonLake reported disappointing results from its Phase 3 VELA trials for sonelokimab, with one trial failing to meet its primary endpoint and the other showing only modest gains compared to placebo [1] - Following the trial results, MoonLake's stock price plummeted by $55.75 per share, a decrease of 89.93%, closing at $6.24 per share on September 29, 2025 [1] Company Overview - MoonLake Immunotherapeutics is a company listed on NASDAQ under the ticker MLTX [1] - The company is involved in the development of immunotherapeutic treatments, specifically focusing on sonelokimab [1] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [2] - The firm has successfully recovered multimillion-dollar damages on behalf of class members in the past [2]